Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia
Abstract Background Sodium zirconium cyclosilicate (SZC) has recently emerged as a therapeutic option for the management of acute hyperkalemia. Nevertheless, the relative effectiveness, safety, and financial considerations of SZC therapy versus conventional hemodialysis therapy remain uncertain. Met...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-11-01
|
Series: | Renal Replacement Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s41100-023-00512-0 |
_version_ | 1797556313099599872 |
---|---|
author | Hayato Fujioka Teruhiko Imamura Tsutomu Koike Shingo Yokoyama Kota Kakeshita Hidenori Yamazaki Koichiro Kinugawa |
author_facet | Hayato Fujioka Teruhiko Imamura Tsutomu Koike Shingo Yokoyama Kota Kakeshita Hidenori Yamazaki Koichiro Kinugawa |
author_sort | Hayato Fujioka |
collection | DOAJ |
description | Abstract Background Sodium zirconium cyclosilicate (SZC) has recently emerged as a therapeutic option for the management of acute hyperkalemia. Nevertheless, the relative effectiveness, safety, and financial considerations of SZC therapy versus conventional hemodialysis therapy remain uncertain. Methods In this retrospective study, we embarked upon a comparative analysis encompassing the financial aspects, safety profiles, and efficacy metrics associated with SZC therapy and hemodialysis in patients grappling with acute hyperkalemia. No patients had systemic congestion or uremia. Results A total of 21 patients (median 81 years old, 14 men) were included; 14 received SZC therapy and seven underwent hemodialysis. Acute hyperkalemia improved immediately within several days without any procedure-related adverse events, regardless of therapeutic interventions (p < 0.05 for both). Total medical expenses were significantly lower in the SZC group than in the hemodialysis group (55,596 [43,652, 69,761] vs. 419,768 [354,270, 514,700] Japanese yen, p < 0.001). Conclusions In the realm of acute hyperkalemia management, SZC therapy emerges as an economically judicious alternative, while upholding parity in terms of safety and effectiveness when compared with the conventional hemodialysis paradigm—unless complicated by systemic congestion or uremia. The pressing task at hand revolves around the discernment of the optimal patient demographic for SZC therapy within the ambit of acute hyperkalemia. |
first_indexed | 2024-03-10T17:01:01Z |
format | Article |
id | doaj.art-990ed8c4a4c84241b01516be4eb6ba87 |
institution | Directory Open Access Journal |
issn | 2059-1381 |
language | English |
last_indexed | 2024-03-10T17:01:01Z |
publishDate | 2023-11-01 |
publisher | BMC |
record_format | Article |
series | Renal Replacement Therapy |
spelling | doaj.art-990ed8c4a4c84241b01516be4eb6ba872023-11-20T10:59:04ZengBMCRenal Replacement Therapy2059-13812023-11-01911910.1186/s41100-023-00512-0Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemiaHayato Fujioka0Teruhiko Imamura1Tsutomu Koike2Shingo Yokoyama3Kota Kakeshita4Hidenori Yamazaki5Koichiro Kinugawa6The Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaThe Second Department of Internal Medicine, University of ToyamaAbstract Background Sodium zirconium cyclosilicate (SZC) has recently emerged as a therapeutic option for the management of acute hyperkalemia. Nevertheless, the relative effectiveness, safety, and financial considerations of SZC therapy versus conventional hemodialysis therapy remain uncertain. Methods In this retrospective study, we embarked upon a comparative analysis encompassing the financial aspects, safety profiles, and efficacy metrics associated with SZC therapy and hemodialysis in patients grappling with acute hyperkalemia. No patients had systemic congestion or uremia. Results A total of 21 patients (median 81 years old, 14 men) were included; 14 received SZC therapy and seven underwent hemodialysis. Acute hyperkalemia improved immediately within several days without any procedure-related adverse events, regardless of therapeutic interventions (p < 0.05 for both). Total medical expenses were significantly lower in the SZC group than in the hemodialysis group (55,596 [43,652, 69,761] vs. 419,768 [354,270, 514,700] Japanese yen, p < 0.001). Conclusions In the realm of acute hyperkalemia management, SZC therapy emerges as an economically judicious alternative, while upholding parity in terms of safety and effectiveness when compared with the conventional hemodialysis paradigm—unless complicated by systemic congestion or uremia. The pressing task at hand revolves around the discernment of the optimal patient demographic for SZC therapy within the ambit of acute hyperkalemia.https://doi.org/10.1186/s41100-023-00512-0Chronic kidney diseasePotassium binderMedical cost |
spellingShingle | Hayato Fujioka Teruhiko Imamura Tsutomu Koike Shingo Yokoyama Kota Kakeshita Hidenori Yamazaki Koichiro Kinugawa Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia Renal Replacement Therapy Chronic kidney disease Potassium binder Medical cost |
title | Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia |
title_full | Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia |
title_fullStr | Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia |
title_full_unstemmed | Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia |
title_short | Sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia |
title_sort | sodium zirconium cyclosilicate hydrate reduces medical expenses compared with hemodialysis in patients with acute hyperkalemia |
topic | Chronic kidney disease Potassium binder Medical cost |
url | https://doi.org/10.1186/s41100-023-00512-0 |
work_keys_str_mv | AT hayatofujioka sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia AT teruhikoimamura sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia AT tsutomukoike sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia AT shingoyokoyama sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia AT kotakakeshita sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia AT hidenoriyamazaki sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia AT koichirokinugawa sodiumzirconiumcyclosilicatehydratereducesmedicalexpensescomparedwithhemodialysisinpatientswithacutehyperkalemia |